Severe attack of Henoch-Schönlein purpura with neurologic involvement during adalimumab treatment for Crohn's disease.
Tumour necrosis factor-α (TNF-α) inhibitors have revolutionized the management of chronic inflammatory conditions. A number of cutaneous adverse events have been reported with TNF inhibition, including vasculitis. Most reactions are mild and rarely warrant treatment withdrawal. Here we describe a patient with Crohn's disease treated with adalimumab in whom severe multivisceral Henoch-Schönlein purpura developed, including neurologic involvement, requiring definitive TNF blocker withdrawal.